Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

NCT06364410 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

NIH

Sponsor class

Conditions

Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Gastric Carcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Locally Advanced Malignant Solid Neoplasm
Metastatic Gastric Carcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Metastatic Malignant Solid Neoplasm
Unresectable Gastric Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Unresectable Malignant Solid Neoplasm

Interventions

DRUG: Azenosertib
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography Test
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Multigated Acquisition Scan
BIOLOGICAL: Trastuzumab Deruxtecan

Sponsor

National Cancer Institute (NCI)